连续流左心室辅助装置患者胃肠道出血的药物治疗管理
连续流左心室辅助装置(CF-LVAD)患者胃肠道出血(GIB)风险持续存在,机制涉及获得性von Willebrand病、血管发育不良及胃肠道动静脉畸形等多因素;现有药物疗法疗效数据稀疏,需前瞻性研究;本文综述病理生理及治疗选择并给出用药方案建议。
要点
- CF-LVAD患者GIB机制多因素,包括获得性von Willebrand病、血管发育不良和胃肠道动静脉畸形。
- GIB病史和高龄是CF-LVAD患者发生GIB的额外风险因素。
- 现有药物疗法疗效数据稀疏,需大型前瞻性研究推进管理。
核心结论
- CF-LVAD患者GIB的药物治疗管理需基于病理生理机制,但现有疗效数据稀疏,需前瞻性研究。
研究设计与样本
- 本文为综述,讨论CF-LVAD相关GIB的已知病理生理过程及文献中的治疗选择。
主要发现
- CF-LVAD患者GIB的成因可能为多因素,包括获得性von Willebrand病、血管发育不良和胃肠道动静脉畸形。
- GIB病史和年龄增加是CF-LVAD患者发生GIB的额外风险因素。
- 多种药物疗法已被使用,但关于其总体疗效的数据仍然稀疏。
临床怎么用
- 基于作用机制与CF-LVAD相关GIB已知病理生理过程的关联,讨论潜在治疗选择。
- 为发生GIB的CF-LVAD患者构建药物治疗方案提供建议。
局限性
- 围绕药物疗法总体疗效的数据仍然稀疏。
- 需要更大规模的前瞻性研究以进一步推进这一并发症的管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Continuous-flow left ventricular assist devices (CF-LVADs) have become an integral component of the management in patients with advanced heart failure, serving as destination therapy or as a bridge to heart transplantation. Despite significant advances in the design and longevity of the device, the ongoing risk for bleeding remains a significant concern. The genesis of gastrointestinal bleeding (GIB) in patients with CF-LVADs is likely multifactorial and may include components of acquired von Willebrand disease, angiodysplasia, and gastrointestinal arteriovenous malformations, as well as additional risk factors such as history of GIB and increased age. Several pharmacotherapy options have been used, but the data surrounding their overall efficacy remain sparse. The necessity for larger prospective studies is essential to further advance the management of this devastating complication. Within this review, we discuss the known pathophysiologic process of CF-LVAD-related GIB and highlight the therapeutic options discussed within the literature. In addition, we discuss potential therapeutic options based on mechanisms of action as they correlate to known pathophysiologic processes of CF-LVAD-related GIB. Finally, we provide recommendations for constructing drug therapy regimens in patients with CF-LVADs who develop GIB.
引用
- Sieg AC, Moretz JD, Horn E, et al. Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices. Pharmacotherapy. 2017. PMID: 28833332. doi:10.1002/phar.2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。